Heidi Kempinski
Chief Operating Officer at Aegle Therapeutics Corp.
Profile
Heidi Kempinski is currently the Senior Vice President & Head-Operations at Aegle Therapeutics Corp., Senior Principal & Operating Executive at Tellus BioVentures LLC, and Chief Operating Officer at Praeventix, Inc. Previously, she worked as Vice President-Pharmaceutical Development at Tesaro, Inc. and as VP-Business Operations & Strategic Alliances at GSK Plc from 2019 to 2020.
Heidi Kempinski active positions
Companies | Position | Start |
---|---|---|
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | Chief Operating Officer | 28/09/2020 |
Tellus Bioventures LLC
Tellus Bioventures LLC Investment ManagersFinance Tellus BioVentures LLC (Tellus BioVentures) is a venture capital firm founded in 2019 by Leon O. Moulder. The firm is headquartered in Miromar Lakes, Florida. | Private Equity Investor | 31/07/2020 |
Praeventix, Inc.
Praeventix, Inc. BiotechnologyHealth Technology Praeventix, Inc. is a biotechnology company founded by Dr. Douglas Pippin based on discoveries researched by Dr. Pippin and at Temple University. The company is based in Exton, PA, and was founded by Douglas Pippin. The company is initially focused on the development of pre-clinical candidate pra-523, a potential first-in-class neuromodulatory therapy for pruritus and other potential indications, including IBD. Praeventix is pursuing novel serotonergic therapeutics for inflammatory bowel disease (IBD) and cocaine use disorder (CUD). Douglas Pippin has been the CEO since incorporation. | Chief Operating Officer | - |
Former positions of Heidi Kempinski
Companies | Position | End |
---|---|---|
GSK PLC | Corporate Officer/Principal | 30/06/2020 |
TESARO INC | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
GSK PLC | Health Technology |
Private companies | 4 |
---|---|
Tesaro, Inc.
Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Aegle Therapeutics Corp.
Aegle Therapeutics Corp. BiotechnologyHealth Technology Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL. | Health Technology |
Tellus Bioventures LLC
Tellus Bioventures LLC Investment ManagersFinance Tellus BioVentures LLC (Tellus BioVentures) is a venture capital firm founded in 2019 by Leon O. Moulder. The firm is headquartered in Miromar Lakes, Florida. | Finance |
Praeventix, Inc.
Praeventix, Inc. BiotechnologyHealth Technology Praeventix, Inc. is a biotechnology company founded by Dr. Douglas Pippin based on discoveries researched by Dr. Pippin and at Temple University. The company is based in Exton, PA, and was founded by Douglas Pippin. The company is initially focused on the development of pre-clinical candidate pra-523, a potential first-in-class neuromodulatory therapy for pruritus and other potential indications, including IBD. Praeventix is pursuing novel serotonergic therapeutics for inflammatory bowel disease (IBD) and cocaine use disorder (CUD). Douglas Pippin has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Heidi Kempinski